Indian Patent Office rejects patent for fixed-dose combination of tuberculosis medicines

India’s Patent Office has reportedly rejected a patent application for a fixed-dose combination of three medicines used to treat drug-resistant tuberculosis. The applicant failed to establish patentability, while opponents argued that combining existing medicines into one pill lacked sufficient evidence of improved clinical outcomes, product stability and additional therapeutic benefits.

Join our 1500+ subscribers to get our daily Health Laws and Policy Updates.